Keyphrases
Acute Myeloid Leukemia
19%
Adrenoleukodystrophy
33%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Body Mass Index
13%
Brain Metastases
91%
Cancer Patients
14%
Cardiofaciocutaneous Syndrome
17%
Chemotherapy
26%
Clinical Outcomes
24%
Clinical Trials
12%
Confidence Interval
46%
Cyclophosphamide
17%
Graded Prognostic Assessment
64%
Graft-versus-host Disease (GvHD)
51%
Gynecologic Cancer Survivors
16%
Hazard Ratio
19%
Hematopoietic Cell Transplantation
22%
Hematopoietic Stem Cell Transplantation
30%
High Risk
13%
Hurler Syndrome
16%
In Cancer
13%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
11%
Lung Metastasis
16%
Lymphoma
19%
Malignant Melanoma
12%
Marrow
13%
Median Survival
18%
Melanoma
26%
Menthol
22%
Menthol Cigarettes
17%
Molecular Markers
12%
Myelodysplastic Syndrome
16%
Non-relapse Mortality
13%
Non-small Cell Lung Cancer (NSCLC)
14%
Oncolytic Adenovirus
16%
Outcome Prediction
16%
Overall Survival
48%
Patients with Breast Cancer
13%
Pediatric
16%
Pretransplant
17%
Prognostic Factors
39%
Prognostic Score
15%
Progression-free Survival
14%
Psychosocial Outcomes
13%
RASopathies
12%
Smokers
18%
Transplantation
18%
Tumor Subtype
18%
Umbilical Cord Blood
23%
Unrelated Donor
13%
Medicine and Dentistry
Acute Graft Versus Host Disease
15%
Acute Myelogenous Leukemia
11%
Acute Myeloid Leukemia
27%
Adrenoleukodystrophy
22%
Allogeneic Hematopoietic Stem Cell Transplantation
16%
Allograft
10%
Body Mass Index
14%
Brain Metastasis
77%
Breast Cancer
35%
Cancer Therapy
11%
Cardiofaciocutaneous Syndrome
11%
Cell Transplantation
66%
Chronic Graft Versus Host Disease
11%
Clear Cell Renal Cell Carcinoma
11%
Clinical Trial
26%
Cord Blood
30%
Cumulative Incidence
10%
Cyclophosphamide
11%
Cytomegalovirus
16%
Cytomegalovirus Infection
11%
Diseases
27%
Emergency Department
11%
Gastrointestinal Cancer
11%
Hazard Ratio
17%
Hematopoietic Cell
85%
Hematopoietic Stem Cell Transplantation
31%
Hurler Syndrome
16%
Immunotherapy
12%
Lung Cancer
11%
Magnetic Resonance Imaging
16%
Malignant Neoplasm
24%
Melanoma
33%
Metastatic Carcinoma
40%
Molecular Marker
12%
Myelodysplastic Syndrome
16%
Neoplasm
26%
Neurofibromatosis Type I
11%
Non Small Cell Lung Cancer
15%
Noonan Syndrome
11%
Oncology
10%
Oncolytic Adenovirus
11%
Overall Survival
45%
Pediatrics
17%
Positron Emission Tomography-Computed Tomography
16%
Prognostic Assessment
58%
Prognostic Factor
33%
Progression Free Survival
16%
Radiation Therapy
17%
Skeleton
13%
Stem Cell Transplant
11%